Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rob Sellar

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Hematology/Oncology Clinics of North America|July 5, 2017
Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus RealityRob Sellar, Julie-Aurore Losman
Current Treatment Options in Oncology|September 30, 2011
Redefining transplant in acute leukemiaRob Sellar, Anthony H Goldstone, Hillard M Lazarus
Immunotherapy|June 19, 2026
CAR cellular therapies for acute myeloid leukemia: current landscape and future directionsJure Hederih, James Patrick, Isaac Gannon, et al.
British Journal of Haematology|July 1, 2014
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathwaysKoremu Meja, Chloe Stengel, Rob Sellar, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Hematology/Oncology Clinics of North America|July 5, 2017
Targeting Aberrant Signaling in Myeloid Malignancies: Promise Versus RealityRob Sellar, Julie-Aurore Losman
Current Treatment Options in Oncology|September 30, 2011
Redefining transplant in acute leukemiaRob Sellar, Anthony H Goldstone, Hillard M Lazarus
Immunotherapy|June 19, 2026
CAR cellular therapies for acute myeloid leukemia: current landscape and future directionsJure Hederih, James Patrick, Isaac Gannon, et al.
British Journal of Haematology|July 1, 2014
PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathwaysKoremu Meja, Chloe Stengel, Rob Sellar, et al.
Blood Advances|September 12, 2024
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapyJad Othman, Angela Hwang, Maximillian Brodermann, et al.
Blood|August 30, 2023
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Ing S Tiong, Jenny O'Nions, et al.
Pageof 1